High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 943-951

  Van De Ven, Rieneke ^a   Verbrugge, Sue Ellen ^a   Reurs, Anneke W ^a   Bontkes, Hetty J ^a   Hooijberg, Erik ^a   Jansen, Gerrit ^a   Scheper, Rik J ^a   Scheffer, George L ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

c Kit; Chemotherapy; Dendritic cell differentiation; Doxorubicin

Indexed keywords

CD34 ANTIGEN; DOXORUBICIN; STEM CELL FACTOR RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL SELECTION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LANGERHANS CELL; LOSS OF FUNCTION MUTATION; LYMPHOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; T LYMPHOCYTE SUBPOPULATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD34; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; DOXORUBICIN; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LANGERHANS CELLS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE;

EID: 79959767764     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1003-9     Document Type: Article

References (33)

1. H Andersen EV Barsov MT Trivett, et al. 2007 Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function AIDS Res Hum Retroviruses 23 456 465 17411379 10.1089/aid.2006.0194 1:CAS:528: DC%2BD2sXjvVaqsL8%3D (Pubitemid 46608566)
2. JP Annereau G Szakacs CJ Tucker, et al. 2004 Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance Mol Pharmacol 66 1397 1405 15342794 10.1124/mol.104.005009 1:CAS:528:DC%2BD2cXhtVOit73E (Pubitemid 39564766)
3. L Apetoh F Ghiringhelli A Tesniere, et al. 2007 Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 1050 1059 17704786 10.1038/nm1622 1:CAS:528: DC%2BD2sXhtVSgtr3E (Pubitemid 47517504)
4. MC Bene M Bernier RO Casasnovas, et al. 1998 The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European group for the Immunological classification of leukemias (EGIL) Blood 92 596 599 9657760 1:CAS:528: DyaK1cXksFaqsrY%3D (Pubitemid 28323723)
5. J Bijl JW van Oostveen M Kreike, et al. 1996 Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue Blood 87 1737 1745 8634419 1:CAS:528:DyaK28XhtlGgsrc%3D (Pubitemid 26068889)
6. A Blair HJ Sutherland 2000 Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117) Exp Hematol 28 660 671 10880752 10.1016/S0301-472X(00)00155-7 1:CAS:528:DC%2BD3cXks1ajtbY%3D (Pubitemid 30398523)
7. HJ Bontkes JJ Ruizendaal D Kramer, et al. 2006 Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells J Immunother 29 188 200 16531819 10.1097/01.cji.0000197095.00359.67 1:CAS:528:DC%2BD28Xit1yhtbk%3D
8. RA Briddell VC Broudy E Bruno, et al. 1992 Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor Blood 79 3159 3167 1375842 1:STN:280:DyaK383ot1SksQ%3D%3D
9. N Casares MO Pequignot A Tesniere, et al. 2005 Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J Exp Med 202 1691 1701 16365148 10.1084/jem.20050915 1:CAS:528:DC%2BD2MXhtlCjsrjK (Pubitemid 41815875)
10. A Curti M Fogli M Ratta, et al. 2001 Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+ DR- dendritic cell precursors J Immunol 166 848 854 11145659 1:CAS:528: DC%2BD3MXlvVWjtg%3D%3D (Pubitemid 32060237)
11. TD de Gruijl AJ van den Eertwegh HM Pinedo, et al. 2008 Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines Cancer Immunol Immunother 57 1569 1577 18523771 10.1007/s00262-008- 0536-z 1:CAS:528:DC%2BD1cXovFyisbs%3D
12. M De Waele W Renmans GK Vander, et al. 2001 Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts Eur J Haematol 66 178 187 11350486 10.1034/j.1600-0609.2001.00320.x (Pubitemid 32324584)
13. L Deville J Hillion E Segal-Bendirdjian 2009 Telomerase regulation in hematological cancers: a matter of stemness? Biochim Biophys Acta 1792 229 239 19419697 1:CAS:528:DC%2BD1MXksVaqsLw%3D
14. SC Dowdy CH Boardman TO Wilson, et al. 2002 Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer Am J Obstet Gynecol 186 1167 1173 12066092 10.1067/mob.2002.123820 1:CAS:528:DC%2BD38XlsFOqu7g%3D (Pubitemid 34665054)
15. Y Gunji M Nakamura H Osawa, et al. 1993 Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells Blood 82 3283 3289 7694677 1:CAS:528:DyaK2cXivVWhsw%3D%3D (Pubitemid 23356697)
16. ZB Hu W Ma M Zaborski, et al. 1996 Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3 Leukemia 10 1025 1040 8667638 1:STN:280:DyaK283ms1GisQ%3D%3D (Pubitemid 26235937)
17. E Khoury C Andre S Pontvert-Delucq, et al. 1994 Tumor necrosis factor alpha (TNF alpha) downregulates c-kit proto-oncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNF alpha receptors Blood 84 2506 2514 7522632 1:CAS:528:DyaK2cXmsFens78%3D (Pubitemid 24317382)
18. GD Leonard T Fojo SE Bates 2003 The role of ABC transporters in clinical practice Oncologist 8 411 424 14530494 10.1634/theoncologist.8-5-411 1:CAS:528:DC%2BD3sXoslyls74%3D (Pubitemid 37238869)
19. HJ Long III BJ Monk HQ Huang, et al. 2006 Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a gynecologic oncology group study Gynecol Oncol 100 537 543 16216315 10.1016/j.ygyno.2005.09.023 1:CAS:528:DC%2BD28XhsFKrt78%3D (Pubitemid 43246869)
20. HJ Long III S Rayson KC Podratz, et al. 2002 Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature Am J Clin Oncol 25 547 551 12477995 10.1097/00000421-200212000-00002
21. AJ Masterson CC Sombroek TD de Gruijl, et al. 2002 MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors Blood 100 701 703 12091369 10.1182/blood.V100.2.701 1:CAS:528:DC%2BD38XlsVWgur8%3D (Pubitemid 34761140)
22. SJ Santegoets AJ Masterson PC van der Sluis, et al. 2006 A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+ CD11b+ Langerhans cell precursor J Leukoc Biol 80 1337 1344 16959899 10.1189/jlb.0206111 1:CAS:528:DC%2BD28XhtlSisLnE (Pubitemid 44904972)
23. SJ Santegoets AJ van den Eertwegh AA van de Loosdrecht, et al. 2008 Human dendritic cell line models for DC differentiation and clinical DC vaccination studies J Leukoc Biol 84 1364 1373 18664532 10.1189/jlb.0208092 1:CAS:528:DC%2BD1cXhsVKhsrbM (Pubitemid 352774471)
24. MW Schreurs MA Hermsen RI Geltink, et al. 2005 Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes Blood 106 2663 2670 16002425 10.1182/blood-2004-09-3742 1:CAS:528:DC%2BD2MXhtFantbjO (Pubitemid 41510738)
25. MW Schreurs KB Scholten EW Kueter, et al. 2003 In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones J Immunol 171 2912 2921 12960314 1:CAS:528: DC%2BD3sXmvFGqt7k%3D (Pubitemid 37093512)
26. PJ Snijders M van Duin JM Walboomers, et al. 1998 Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA Cancer Res 58 3812 3818 9731489 1:CAS:528:DyaK1cXlvVyrurk%3D (Pubitemid 28405635)
27. H Strobl M Takimoto O Majdic, et al. 1992 Antigenic analysis of human haemopoietic progenitor cells expressing the growth factor receptor c-kit Br J Haematol 82 287 294 1384648 10.1111/j.1365-2141.1992.tb06420.x 1:CAS:528:DyaK3sXpvFyquw%3D%3D
28. H Ueno E Klechevsky R Morita, et al. 2007 Dendritic cell subsets in health and disease Immunol Rev 219 118 142 17850486 10.1111/j.1600-065X.2007. 00551.x 1:CAS:528:DC%2BD2sXht1Cnt7zI (Pubitemid 47393528)
29. E Ullrich C Menard C Flament, et al. 2008 Dendritic cells and innate defense against tumor cells Cytokine Growth Factor Rev 19 79 92 18155952 10.1016/j.cytogfr.2007.10.009 1:CAS:528:DC%2BD1cXhsleksb4%3D
30. R van de Ven MC de Jong AW Reurs, et al. 2006 Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation J Immunol 176 5191 5198 16621983
31. G von Minckwitz W Jonat P Fasching, et al. 2005 A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 165 172 10.1007/s10549-004-1720-2 1:CAS:528:DC%2BD2MXhtVamsro%3D (Pubitemid 40249050)
32. G von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German breast group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
33. L Zitvogel O Kepp L Aymeric, et al. 2010 Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy Cancer Res 70 23 9538 9543 21098713 10.1158/0008-5472. CAN-10-1003 1:CAS:528:DC%2BC3cXhsFamurzE